Benowitz NL - Search Results

1

CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion.

Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, Benowitz NL, Tyndale RF. Zhu AZ, et al. Among authors: benowitz nl. Clin Pharmacol Ther. 2012 Dec;92(6):771-7. doi: 10.1038/clpt.2012.186. Epub 2012 Nov 14. Clin Pharmacol Ther. 2012. PMID: 23149928 Free PMC article. Clinical Trial.

2

Deficient C-oxidation of nicotine continued.

Benowitz NL, Griffin C, Tyndale R. Benowitz NL, et al. Clin Pharmacol Ther. 2001 Dec;70(6):567. doi: 10.1067/mcp.2001.120252. Clin Pharmacol Ther. 2001. PMID: 11753274 No abstract available.

3

Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.

Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, Tyndale RF, Benowitz NL. Dempsey D, et al. Among authors: benowitz nl. Clin Pharmacol Ther. 2004 Jul;76(1):64-72. doi: 10.1016/j.clpt.2004.02.011. Clin Pharmacol Ther. 2004. PMID: 15229465

4

Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence.

Swan GE, Benowitz NL, Lessov CN, Jacob P 3rd, Tyndale RF, Wilhelmsen K. Swan GE, et al. Among authors: benowitz nl. Pharmacogenet Genomics. 2005 Feb;15(2):115-25. doi: 10.1097/01213011-200502000-00007. Pharmacogenet Genomics. 2005. PMID: 15861035

5

Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy.

Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. Malaiyandi V, et al. Among authors: benowitz nl. Mol Psychiatry. 2006 Apr;11(4):400-9. doi: 10.1038/sj.mp.4001794. Mol Psychiatry. 2006. PMID: 16402128 Clinical Trial.

6

Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics.

Al Koudsi N, Mwenifumbo JC, Sellers EM, Benowitz NL, Swan GE, Tyndale RF. Al Koudsi N, et al. Among authors: benowitz nl. Eur J Clin Pharmacol. 2006 Jun;62(6):481-4. doi: 10.1007/s00228-006-0113-3. Epub 2006 Apr 28. Eur J Clin Pharmacol. 2006. PMID: 16758265

7

Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation.

Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, Benowitz N. Lerman C, et al. Clin Pharmacol Ther. 2006 Jun;79(6):600-8. doi: 10.1016/j.clpt.2006.02.006. Epub 2006 May 11. Clin Pharmacol Ther. 2006. PMID: 16765148 Clinical Trial.

8

Determinants of the rate of nicotine metabolism and effects on smoking behavior.

Johnstone E, Benowitz N, Cargill A, Jacob R, Hinks L, Day I, Murphy M, Walton R. Johnstone E, et al. Clin Pharmacol Ther. 2006 Oct;80(4):319-30. doi: 10.1016/j.clpt.2006.06.011. Clin Pharmacol Ther. 2006. PMID: 17015050

9

CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.

Benowitz NL, Swan GE, Jacob P 3rd, Lessov-Schlaggar CN, Tyndale RF. Benowitz NL, et al. Clin Pharmacol Ther. 2006 Nov;80(5):457-67. doi: 10.1016/j.clpt.2006.08.011. Clin Pharmacol Ther. 2006. PMID: 17112802 Clinical Trial.

10

The pharmacogenetics research network: from SNP discovery to clinical drug response.

Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I; Pharmacogenetics Research Network. Giacomini KM, et al. Among authors: benowitz nl. Clin Pharmacol Ther. 2007 Mar;81(3):328-45. doi: 10.1038/sj.clpt.6100087. Clin Pharmacol Ther. 2007. PMID: 17339863 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

800 results

Search Page